First-in-human trial of a novel anti-trop-2 Antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors

Clinical Cancer Research

Volumn 21, Issue 17, 2015, Pages 3870-3878

  Starodub, Alexander N ^a   Ocean, Allyson J ^b   Shah, Manish A ^b   Guarino, Michael J ^c   Picozzi, Vincent J ^d   Vahdat, Linda T ^b   Thomas, Sajeve S ^e   Govindan, Serengulam V ^f   Maliakal, Pius P ^f   Wegener, William A ^f   Hamburger, Steven A ^f   Sharkey, Robert M ^f   Goldenberg, David M ^f  

^a INDIANA UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c CHRISTIANA CARE HEALTH SYSTEM   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f IMMUNOMEDICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BNC 105; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; ONARTUZUMAB; OXALIPLATIN; PACLITAXEL; PLACEBO; PREDNISONE; REGORAFENIB; SACITUZUMAB GOVITECAN; TOPOTECAN; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; CAMPTOTHECIN; CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER CANCER; BLEEDING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNOGENICITY; INFUSION RELATED REACTION; KIDNEY CANCER; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NON SMALL CELL LUNG CANCER; OVARY CARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RADIOIMMUNOTHERAPY; RASH; SIDE EFFECT; SMALL CELL LUNG CANCER; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TONSIL CANCER; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VERY ELDERLY; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG MONITORING; METABOLISM; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASMS; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL ADHESION MOLECULES; COMBINED MODALITY THERAPY; DRUG MONITORING; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84930220109     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3321     Document Type: Article

References (19)

1. Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov 2011; 11: 19-20.
2. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013; 64: 15-29.
3. Krop I, Winer EP. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Clin Cancer Res 2014; 20: 15-20.
4. Moon SJ, Govindan SV, Cardillo TM, D'Souza CA, Hansen HJ, Goldenberg DM. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem 2008; 51: 6916-26.
5. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEA-CAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 2009; 15: 6052-61.
6. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7: 2182-94.
7. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 2011; 17: 3157-69.
8. Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV, Goldenberg DM. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther 2013; 12: 968-78.
9. Stein R, Basu A, Chen S, Shih LB, Goldenberg DM. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer 1993; 55: 938-46.
10. Ambrogi F, Fornili M, Boracchi P, Trerotola M, Relli V, Simeone P, et al. Trop-2 is a determinant of breast cancer survival. PLoS ONE 2014; 9: e96993.
11. Cubas R, Li M, Chen C, Yao Q. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 2009; 1796: 309-14.
12. Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 2013; 32: 222-33.
13. Trerotola M, Guerra E, Alberti S. Letter to the editor: efficacy and safety of anti-Trop antibodies, R. Cubas, M. Li, C. Chen and Q. Yao, Biochim Biophys Acta 1796 (2009) 309-1.
14. Biochim Biophys Acta 2010; 1805: 119-20.
15. Camptosar-irinotecan hydrochlorideinjection, solution(prescribing information, package insert). http://labeling.pfizer.com/ShowLabeling.aspx?id=533Pfizer; 2012.
16. Picozzi VJ, Ocean AJ, Starodub AN, Thomas SS, Maliakal PP, Govindan SV, et al. IMMU-132, a new antibody-drug conjugate (ADC), evaluated in patients with advanced, metastatic, pancreatic ductal adenocarcinoma (mPC): Results of a Phase I/II trial. Presented at the American Association for Cancer Research Special Conference "Pancreatic Cancer: Innovations in Research and Treatment". New Orleans, LA. Philadelphia, PA: AACR; 2014. Abstract nr B99.
17. Bardia A, Starodub AN, Moroose RL, Mayer IA, Diamond JR, Chuang E, et al. IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552). In: Proceedings of the 37th Annual CTRC-AACRSan Antonio Breast Cancer Symposium; 2014 Dec 9-13; San Antonio (TX): AACR; 2014.
18. Goldenberg DM, Rossi EA, Govindan SV, Cardillo TM, McBride WJ, Zalath M, et al. Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers. J Clin Oncol 2014; 32: abstr 3107.
19. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol 2002; 20: 3293-301.